braf v600e Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (2)

Interventional (2)

JS InnoPharm, LLC (1)
Memorial Sloan Kettering Cancer Center (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadliver metastasis

I am/have/hadplat

I am/have/hadcarcinoma

I am/have/hadBRAF

I am/have/hadthyroid cancer

I am/have/hadlipase

I am/have/hadgene fusion

I am/have/hadnon-small cell lung cancer

I am/have/hadtumor progression

I am/have/hadbraf v600e

I am/have/hadneutrophil count

I am/have/hadinvestigational treatment

I am/have/hadpet/ct

I am/have/hadcoagulation therapy

I am/have/hadbraf v600e mutation positive

I am/have/hadbrain metastases

I am/have/hadgilbert's syndrome

I am/have/hadpet/ct scan

I am/have/hadmetastatic melanoma

I am/have/hadtargeted therapy

added new label for I am/have/had

more

I am looking for

I am looking forras-gef

I am looking foravid

I am looking forimmunomodulators

I am looking fordabrafenib

I am looking forvemurafenib

I am looking fortotal bilirubin

I am looking forimmunomodulator

I am looking foradjuvant

I am looking forcopanlisib

I am looking forras-gap

I am looking forlipase

I am looking formelanoma

I am looking foripilimumab

I am looking formek inhibitor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

mek inhibitor

liver metastasis

BRAF

ras-gap

gene fusion

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors. This study is also being done to find out the highest doses of copanlisib and vemurafenib that, when given …

plat

carcinoma

BRAF

copanlisib

thyroid cancer

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.